Literature DB >> 21218461

Characteristics of the coexistence of melanoma and renal cell carcinoma.

Eve Maubec1, Valérie Chaudru, Hamida Mohamdi, Florent Grange, Jean-Jacques Patard, Stéphane Dalle, Béatrice Crickx, Brigitte Bressac-de Paillerets, Florence Demenais, Marie-Françoise Avril.   

Abstract

BACKGROUND: Patients with melanoma (MM) have an increased risk of kidney cancer, and there is an excess risk of MM among patients with renal cell carcinoma (RCC). The objective of the current study was to analyze a series of 42 patients with both MM and RCC to identify clinical and pathologic features as well as risk factors of this association.
METHODS: Clinical and pathologic characteristics of 42 patients who developed both MM and RCC (the MM + RCC series) were compared with 2 published series in each cancer alone: a series of 293 patients with MM (MM series) and a series of 1527 patients with RCC (RCC series).
RESULTS: RCC was diagnosed concomitantly or after MM in 83% of patients in the MM + RCC series. Those patients displayed a high proportion of asymptomatic RCC at diagnosis (70%) and a higher frequency of stage I tumors (61%) than patients in the RCC series. Compared with the MM series, patients in the MM + RCC series more often were men, had a higher frequency of blond/red hair, had poor tanning ability, and had a higher number of nevi. In addition, patients in the MM + RCC series had a high aggregation of other malignancies (mainly skin cancers) and a significantly higher frequency of family history of MM (P = .005). Only 2 cyclin-dependent kinase 2A gene (CDKN2A) germline mutations were identified among patients in the MM + RCC series who also were members of MM-prone families.
CONCLUSIONS: The high aggregation of cancers among patients in the MM + RCC series and the familial clustering of MM argued for a genetic predisposition that may be partly independent of CDKN2A. Cancer 2010.
© 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21218461     DOI: 10.1002/cncr.25562

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Authors:  Corine Bertolotto; Fabienne Lesueur; Sandy Giuliano; Thomas Strub; Mahaut de Lichy; Karine Bille; Philippe Dessen; Benoit d'Hayer; Hamida Mohamdi; Audrey Remenieras; Eve Maubec; Arnaud de la Fouchardière; Vincent Molinié; Pierre Vabres; Stéphane Dalle; Nicolas Poulalhon; Tanguy Martin-Denavit; Luc Thomas; Pascale Andry-Benzaquen; Nicolas Dupin; Françoise Boitier; Annick Rossi; Jean-Luc Perrot; Bruno Labeille; Caroline Robert; Bernard Escudier; Olivier Caron; Laurence Brugières; Simon Saule; Betty Gardie; Sophie Gad; Stéphane Richard; Jérôme Couturier; Bin Tean Teh; Paola Ghiorzo; Lorenza Pastorino; Susana Puig; Celia Badenas; Hakan Olsson; Christian Ingvar; Etienne Rouleau; Rosette Lidereau; Philippe Bahadoran; Philippe Vielh; Eve Corda; Hélène Blanché; Diana Zelenika; Pilar Galan; François Aubin; Bertrand Bachollet; Céline Becuwe; Pascaline Berthet; Yves Jean Bignon; Valérie Bonadona; Jean-Louis Bonafe; Marie-Noëlle Bonnet-Dupeyron; Fréderic Cambazard; Jacqueline Chevrant-Breton; Isabelle Coupier; Sophie Dalac; Liliane Demange; Michel d'Incan; Catherine Dugast; Laurence Faivre; Lynda Vincent-Fétita; Marion Gauthier-Villars; Brigitte Gilbert; Florent Grange; Jean-Jacques Grob; Philippe Humbert; Nicolas Janin; Pascal Joly; Delphine Kerob; Christine Lasset; Dominique Leroux; Julien Levang; Jean-Marc Limacher; Cristina Livideanu; Michel Longy; Alain Lortholary; Dominique Stoppa-Lyonnet; Sandrine Mansard; Ludovic Mansuy; Karine Marrou; Christine Matéus; Christine Maugard; Nicolas Meyer; Catherine Nogues; Pierre Souteyrand; Laurence Venat-Bouvet; Hélène Zattara; Valérie Chaudru; Gilbert M Lenoir; Mark Lathrop; Irwin Davidson; Marie-Françoise Avril; Florence Demenais; Robert Ballotti; Brigitte Bressac-de Paillerets
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

2.  Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.

Authors:  Gregory W Hosier; Matthew T Roberts
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

Review 3.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

Review 4.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

5.  Coexistent metastatic melanoma of the kidney with unknown primary and renal cell carcinoma.

Authors:  Maulik Dhandha; Melinda B Chu; John M Richart
Journal:  BMJ Case Rep       Date:  2012-12-14

6.  Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Cecilia Luci; Paola Corsetti; Stefano Calvieri
Journal:  Ecancermedicalscience       Date:  2013-05-07

7.  Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma.

Authors:  Ewelina Pośpiech; Janusz Ligęza; Wacław Wilk; Aniela Gołas; Janusz Jaszczyński; Andrzej Stelmach; Janusz Ryś; Aleksandra Blecharczyk; Anna Wojas-Pelc; Jolanta Jura; Wojciech Branicki
Journal:  Biomed Res Int       Date:  2015-04-06       Impact factor: 3.411

8.  Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report.

Authors:  Adela-Raluca Oprea; Arnaud Benas; Andrei Havasi; Alecsandra Gorzo; Stefan Spinu; Daniel Sur; Claudia Burz
Journal:  Cureus       Date:  2022-06-27

9.  On the Bayesian Derivation of a Treatment-based Cancer Ontology.

Authors:  Michael Gao; Jeremy Warner; Peter Yang; Gil Alterovitz
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2014-04-07

10.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.